Workflow
灵康转债
icon
Search documents
新股发行及今日交易提示-20250801
New Stock Issuance - Guangdong JianKe issued new shares at a price of 6.56 on August 1, 2025[1] - ShenKe Co., Ltd. has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] Market Alerts - ST Zitian reported significant abnormal fluctuations on July 21, 2025[1] - ST Suwu experienced abnormal fluctuations on July 30, 2025[1] - ST Xizang Tianlu reported significant abnormal fluctuations on August 1, 2025[1] Other Notable Announcements - Huaneng Electric's announcement was made on August 1, 2025, regarding its stock code 603063[1] - ST Sai Long's announcement was made on August 1, 2025, with stock code 002898[1] - ST Green Kang's announcement was made on July 31, 2025, with stock code 002868[1]
31日投资提示:灵康转债下修到底
集思录· 2025-07-30 12:45
Group 1 - The core viewpoint of the article discusses recent developments in the Chinese stock market, particularly focusing on new stock listings and convertible bonds [1] - The new stock "Youli Intelligent" on the Beijing Stock Exchange has a threshold of 6.47 million [1] - The "Lincang Convertible Bond" is undergoing a down adjustment [1] - The "Gansu Energy Chemical" has resumed production at its Wangjiashan Coal Mine, well number one [1] - The "Aofei Convertible Bond" will not be forcibly redeemed [1] - "Dongjie Intelligent" is undergoing changes in its controlling shareholder's upper-level equity structure, which may lead to a change in the actual controller [1] - The "Xianle Convertible Bond," "Shengxun Convertible Bond," and "Jingrui Convertible Bond 2" will not undergo down adjustments [1] - "Dingjia Precision" has been listed as a new stock on the Beijing Stock Exchange [1]
灵康药业: 2025年第一次临时股东大会会议资料
Zheng Quan Zhi Xing· 2025-07-23 16:14
Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 on July 30 at 14:30 in Hangzhou, Zhejiang [1] - The agenda includes signing in, reviewing proposals, voting, announcing results, and waiting for online voting results [1][2] - The board of directors is proposing to lower the conversion price of "Lingkang Convertible Bonds" to support long-term stable development and optimize the capital structure [3] Group 2 - The board seeks authorization from the shareholders to handle matters related to the adjustment of the conversion price, including determining the new price and effective date [3] - The authorization is valid from the date of approval at the shareholders' meeting until the completion of the related work [3]
灵康药业: 关于董事会提议向下修正“灵康转债”转股价格的公告
Zheng Quan Zhi Xing· 2025-07-14 16:34
Core Viewpoint - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. proposes to lower the conversion price of "Lingkang Convertible Bonds" due to the stock price being below 85% of the current conversion price for at least 15 out of the last 30 trading days [1][4]. Summary by Sections 1. Basic Information of Convertible Bonds - Lingkang Pharmaceutical issued 5.25 million convertible bonds on December 1, 2020, with a face value of 100 yuan each, totaling 525 million yuan [2]. - The bonds are traded under the name "Lingkang Convertible Bonds" with the code "113610" [2]. 2. Conversion Price Adjustment Terms and Trigger Conditions - The conversion price can be adjusted if the stock price is below the current conversion price for at least 15 out of 30 consecutive trading days [3]. - The initial conversion price was set at 8.81 yuan per share, with the latest adjustment bringing it down to 8.00 yuan per share [2]. 3. Procedures for Price Adjustment Proposal - The board meeting on July 14, 2025, approved the proposal to lower the conversion price and will submit it to the shareholders' meeting for approval [4]. - The adjusted conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the shareholders' meeting and the previous trading day's average [5].
灵康药业: 第四届董事会第三十三次会议决议公告
Zheng Quan Zhi Xing· 2025-07-14 16:23
Group 1 - The board of directors of Lingkang Pharmaceutical Group Co., Ltd. held its 33rd meeting on July 14, 2025, to discuss the downward adjustment of the conversion price of "Lingkang Convertible Bonds" [1][2] - The board proposed to authorize the board to handle matters related to the adjustment of the conversion price, including determining the new conversion price and effective date [1] - The meeting was attended by all 7 directors, and the resolution was deemed legal and effective [1][2] Group 2 - The proposal to adjust the conversion price requires approval at the company's first extraordinary general meeting of shareholders in 2025 [2]
15日投资提示:灵康转债提议下修
集思录· 2025-07-14 14:31
Group 1 - Lingkang Convertible Bond: The board proposed a downward adjustment [1] - Shanshi Convertible Bond: The downward adjustment is nearing the bottom [1] - Guoda Convertible Bond, Yong'an Convertible Bond, Beilu Convertible Bond, Feilu Convertible Bond: Strong redemption [1] Group 2 - Yuanshin Industrial: The actual controller's concerted actor plans to reduce holdings by no more than 1.53% of the company's shares [1] - Tongwei Co., Ltd.: Expected net loss of 4.9 billion to 5.2 billion yuan in the first half of the year [1] - Lutai A: Expected net profit of 330 million to 370 million yuan for the first half of 2025, a year-on-year increase of 94.62% to 118.21% [1] Group 3 - Shunbo Alloy: Expected net profit of 150 million to 190 million yuan for the first half of 2025, a year-on-year increase of 78.81% to 126.49% [1] - Quanfeng Automotive: Expected net loss of 185 million to 155 million yuan for the first half of 2025 [1] - Suli Co., Ltd.: Expected net profit of 72 million to 86 million yuan for the first half of 2025, a year-on-year increase of 1008% to 1223% [1] Group 4 - Longi Green Energy: Expected net loss of 2.4 billion to 2.8 billion yuan for the first half of 2025 [1] - Linggang Co., Ltd.: Expected net loss of 577 million yuan for the first half of 2025 [1] - JA Solar Technology: Expected net loss of 2.5 billion to 3 billion yuan for the first half of 2025 [1] - BluFan Medical: Expected net loss of 150 million to 100 million yuan for the first half of 2025 [1] - Shuangliang Energy: The company expects a net profit of -650 million to -500 million yuan for the first half of the year [1]
6月24日投资提示:芳源转债信用评级下调至BBB
集思录· 2025-06-23 15:04
Group 1 - The shareholder of Borui Pharmaceutical, Advanced Manufacturing Industry Investment Fund, plans to reduce its stake by no more than 3% [1] - The shareholder of WISCO New Energy, Shenzhen Anyan, also intends to reduce its stake by no more than 3% [1] - Chuanheng Convertible Bond is subject to forced redemption [1] Group 2 - Fangyuan Convertible Bond's credit rating has been downgraded to BBB [1] - The company's focus on the ternary lithium battery market is seeing a continuous decline in market share, with intensified industry competition [1] - A significant reduction in core customer orders has led to a rapid decline in ternary precursor revenue, and new businesses such as lithium carbonate have yet to contribute to profitability [1] - The company has reported substantial losses for two consecutive years, indicating increased operational pressure [1] - The company's debt scale continues to rise, with high leverage levels and increased liquidity risks [1] Group 3 - Yao Stone Technology's associate company, Yaojie Ankang, has been listed on the main board of the Hong Kong Stock Exchange [1] - Lingkang Convertible Bond and Mingxin Convertible Bond will not undergo adjustments [1]
灵康药业: 关于“灵康转债”2025年跟踪评级结果的公告
Zheng Quan Zhi Xing· 2025-06-20 10:13
Core Viewpoint - The company, Lingkang Pharmaceutical Group Co., Ltd., has maintained its credit rating for both the company and its convertible bonds, indicating stable financial health and outlook [1][2]. Summary by Relevant Sections Company Credit Rating - The company's credit rating remains at "A-" with a stable outlook, consistent with the previous rating [1][2]. - The last rating was conducted by Dongfang Jincheng International Credit Assessment Co., Ltd. on June 18, 2024 [1]. Convertible Bond Rating - The credit rating for the "Lingkang Convertible Bonds" is also maintained at "A-" with a stable outlook, showing no change from the previous assessment [2].
灵康药业: 灵康药业集团股份有限公司公开发行A股可转换公司债券受托管理事务报告(2024年度)
Zheng Quan Zhi Xing· 2025-06-20 10:13
Group 1 - The company, Lingkang Pharmaceutical Group Co., Ltd., has publicly issued A-share convertible bonds with a total amount of RMB 517.78 million, consisting of 5.25 million bonds at a face value of RMB 100 each [1][4][9] - The bonds are convertible into the company's A-shares, with an initial conversion price set at RMB 8.81 per share, and the conversion period is from June 7, 2021, to November 30, 2026 [2][3][4] - The company has established a special account for the raised funds, which will be used for specific investment projects, including the construction of a production base [9][10][15] Group 2 - In 2024, the company reported a revenue of RMB 379.78 million, a 92.95% increase from RMB 196.83 million in 2023, but incurred a net loss of RMB 130.76 million, an improvement from a loss of RMB 151.50 million in the previous year [12][13] - The total assets decreased by 22.73% to RMB 1.26 billion from RMB 1.62 billion in 2023, and the net assets also fell by 17.32% to RMB 769.76 million [12][13] - The company has terminated the "Hainan Lingkang Pharmaceutical Production Base Construction Project (Phase I)" due to significant changes in project feasibility and will retain the remaining raised funds in the special account [14][15] Group 3 - The company has a credit rating of A- for its bonds as of June 2024, with a stable outlook, reflecting a downgrade from AA- in previous years [12][13] - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds, and there have been no violations reported [10][14] - The company has established a management system for the raised funds, ensuring they are used appropriately for the intended projects [10][14]
灵康药业: 可转债转股结果暨股份变动公告
Zheng Quan Zhi Xing· 2025-04-02 14:25
Key Points - The core viewpoint of the announcement is the update on the conversion status of the company's convertible bonds, specifically the "Lingkang Convertible Bonds" and the impact on the company's share capital [1][2][3] Group 1: Convertible Bond Conversion Status - From January 1, 2025, to March 31, 2025, the amount converted from "Lingkang Convertible Bonds" was 6,000 RMB, resulting in 750 shares, which represents 0.0001% of the total shares before conversion [1][2] - As of March 31, 2025, a total of 67,196,000 RMB of "Lingkang Convertible Bonds" has been converted into company stock, amounting to 7,804,755 shares, which is 1.0940% of the total shares before conversion [1][2] - As of March 31, 2025, the amount of "Lingkang Convertible Bonds" that has not been converted, excluding those that have been repurchased, is 252,978,000 RMB, accounting for 48.1863% of the total issuance [3] Group 2: Issuance Overview - The company issued 5.25 million convertible bonds at a face value of 100 RMB each, with a total issuance amount of 525 million RMB, approved by the China Securities Regulatory Commission [1] - The bonds became convertible into the company's A-shares starting June 7, 2021, with a conversion price set at 8.00 RMB per share [2] - The company executed a buyback of 2,048,260 bonds from June 24 to June 28, 2024, with the repurchase funds distributed on July 3, 2024 [2]